Trial Profile
The safety outcome and visual function in eye treated with 0.2 μg/day fluocinolone acetonide (FAc) for diabetic macular oedema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 17 Apr 2018 New trial record